AVANT BIO and Portfolio Company Intrepid Labs Earn Nominations for Prestigious Prix Galien USA Awards

• AVANT BIO nominated by the prestigious Foundation Galien for the Prix Galien Award in the "Incubators, Accelerators and Equity" category.
• Unique distinction of having a portfolio company also receiving a nomination in the "Best Start Up" category.

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- AVANT BIO, a pioneering early stage and growth equity firm, announces that it has been nominated for the Prix Galien USA award in the "Incubators, Accelerators and Equity" category and Intrepid Labs, an AVANT BIO portfolio company has been nominated for "Best Start Up". These nominations are in line with AVANT BIO's mission to invest in high-impact companies at the convergence of groundbreaking technologies and an enhanced understanding of biology.

Established in 1970, the annual Prix Galien Awards are presented by The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences. For the 2025 edition of Prix Galien USA, AVANT BIO is one of 12 nominees in its category, while Intrepid Labs was selected from a field of 55 companies. As nominees, both companies will be taking part in the Galien Forum business meetings and Galien Awards Gala in New York in October with industry experts and key actors in the US healthcare sector.

"We are deeply honored to be nominated for the prestigious Prix Galien award. This recognition underscores the value and impact of our investment focus. To be acknowledged alongside such distinguished companies in the industry is both humbling and inspiring," said Daniella Kranjac, Founding GP, AVANT BIO. "We are also thrilled that our most recent investment, Intrepid Labs, has been nominated in the extremely competitive start-up category. Their use of artificial intelligence (AI) and robotics is transforming drug formulation development through effective formulations that improve clinical performance."

About AVANT BIO

AVANT BIO is a growth equity firm focused on the enabling technologies shaping how tomorrow's therapeutics are discovered, developed, and manufactured with an investment focus that accelerates new growth and innovation at various stages of company development. With a commitment to amplifying value and a forward-looking investment strategy, AVANT BIO is primed to unlock the full potential of therapeutic enabling technologies, TechBio, and Healthtech.

For further information, including opportunities to partner, visit www.avant.bio. Follow AVANT BIO on LinkedIn for the latest news and industry insights.

SOURCE AVANT BIO LLC